Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavodelpar in Primary Mitochondrial Myopathy (STRIDE)
NCT04535609Phase 2Completed
- Sponsor
- Reneo Pharmaceuticals
- Start
- May 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in primary mitochondrial myopathy (PMM) comparing Mavodelpar with Placebo (2 arms). Primary endpoint: Change in Distance Walked During a 12 Minute Walk Test at 24 weeks. Started May 2021; status: completed.
02
Drugs
mavodelpar
03
Conditions
primary mitochondrial myopathy (PMM)
Beyond the preview
Go deeper on NCT04535609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535609.